2.73
-0.13(-4.55%)
Currency In USD
Address
7000 Shoreline Court
Brisbane, CA 94080
United States of America
Phone
415 798 8589
Website
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
November 12, 2012
| Name | Title | Pay | Year Born |
| Stephen R. Brady | Chief Executive Officer, President & Director | 894,300 | 1970 |
| Nicholas Maestas | Chief Financial Officer, Head of Corporate Strategy & Secretary | 465,615 | 1980 |
| Samuel Whiting | Executive Vice President, Chief Medical Officer and Head of R&D | 671,387 | 1966 |
| Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | 0 | 1989 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.